Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

Kimmo Porkka, MD, PhD, H. Jean Khoury, Ronald Paquette, Yousif Matloub, David Liu, Ritwik Sinha, Jorge Cortes

Blood (2008) 112 (11): 3242.

https://doi.org/10.1182/blood.V112.11.3242.3242

Published: 2008

Journal Articles

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Michele Baccarani, MD, Gianantonio Rosti, Giuseppe Saglio, MD, Jorge Cortes, Richard Stone, Dietger W. Niederwieser, MD, Eric Bleickardt, Ritwik Sinha, Bengt Simonsson

Blood (2008) 112 (11): 450.

https://doi.org/10.1182/blood.V112.11.450.450

Published: 2008

Journal Articles

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Michael W.N. Deininger, MD, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Blood (2008) 112 (11): 3236.

https://doi.org/10.1182/blood.V112.11.3236.3236

Published: 2008

Journal Articles

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Jorge Cortes, MD, Michael Mauro, Susan O’Brien, Gautam Borthakur, William Wierda, Yousif Matloub, Ritwik Sinha, David Liu, Hagop Kantarjian

Blood (2008) 112 (11): 4265.

https://doi.org/10.1182/blood.V112.11.4265.4265

Published: 2008

Journal Articles

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Andreas Hochhaus, MD, Martin C Müller, MD, Jerald Radich, MD, Susan Branford, Benjamin Hanfstein, MD, Philippe Rousselot, MD, PhD, Jeffrey H Lipton, MD, PhD, Eric Bleickardt, Ritwik Sinha, Timothy P Hughes, MD

Blood (2008) 112 (11): 1095.

https://doi.org/10.1182/blood.V112.11.1095.1095

Published: 2008

NARROW

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only